Weight-Loss Drugs Transform Thanksgiving Experience for Users

New generation of obesity medications alter users' relationship with food, raising questions about long-term implications.

New generation of weight-loss drugs, including Wegovy, Ozempic, and Mounjaro, are changing the way users approach food, particularly during traditionally food-centric holidays like Thanksgiving.
These drugs, originally designed to treat diabetes, mimic powerful hormones that regulate appetite and the feeling of fullness, leading to weight loss of 15% to 25% in users.
Some users report greater mental control over their meals and reduced 'food noise', while others experience side effects such as nausea, vomiting, and diarrhea, or lose their appetites entirely.
When users stop taking the drugs, their appetites return and they often regain weight, often faster than they lost it.
Dr. Jens Juul Holst of the University of Copenhagen, one of the researchers who first identified the gut hormone GLP-1, which led to the new class of obesity drugs, questions the long-term impact of altering a basic human drive like appetite.